Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;23(2):122-9.
doi: 10.1097/01.mnh.0000441053.81339.61.

Direct regulation of ENaC by bradykinin in the distal nephron. Implications for renal sodium handling

Affiliations
Review

Direct regulation of ENaC by bradykinin in the distal nephron. Implications for renal sodium handling

Mykola Mamenko et al. Curr Opin Nephrol Hypertens. 2014 Mar.

Abstract

Purpose of review: Locally produced peptide hormones kinins, such as bradykinin, are thought to oppose many of the prohypertensive actions of the renin-angiotensin-aldosterone system. In the kidney, bradykinin, via stimulation of B2 receptors (B2R), favors natriuresis mostly due to the inhibition of tubular Na reabsorption. Recent experimental evidence identifies the epithelial Na channel (ENaC) as a key end effector of bradykinin actions in the distal tubular segments. The focus of this review is the physiological relevance and molecular details of the bradykinin signal to ENaC.

Recent findings: The recent epidemiological GenSalt study demonstrated that genetic variants of the gene encoding B2R show significant associations with the salt sensitivity of blood pressure. Bradykinin was shown to have an inhibitory effect on the distal nephron sodium transport via stimulation of B2 receptor-phospholipase C (B2R-PLC) cascade to decrease ENaC open probability. Genetic ablation of bradykinin receptors in mice led to an augmented ENaC function, particularly during elevated sodium intake, likely contributing to the salt-sensitive hypertensive phenotype. Furthermore, augmentation of bradykinin signaling in the distal nephron was demonstrated to be an important component of the natriuretic and antihypertensive effects of angiotensin converting enzyme inhibition.

Summary: Salt-sensitive inhibition of ENaC activity by bradykinin greatly advances our understanding of the molecular mechanisms that are responsible for shutting down distal tubule sodium reabsorption during volume expanded conditions to avoid salt-sensitive hypertension.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Intracellular signaling pathway implicated in the regulation of ENaC activity by bradykinin in the distal nephron. Bold arrows represent signaling pathways supported by direct experimental evidence; thin arrows indicate additional possible mechanisms of regulation. NH2 and COOH demonstrate amino-termini and carboxyl-termini of ENaC subunits, respectively. AA, arachidonic acid; B2R, bradykinin type 2 receptor; CYP, cytochrome P450; EET, epoxyeicosatrienoic acids; ENaC, epithelial Na+ channel, Gq/11, heterotrimeric G protein Q/11 subtype; NO, nitric oxide; PIP2, phosphatidylinositol 4,5-bisphosphate; PLA2, phospholipase A2; PLC, phospholipase C.
FIGURE 2
FIGURE 2
Principal scheme of interaction between the kallikrein–kinin and renin–angiotensin systems in the distal nephron during different salt intakes. ACE, angiotensin converting enzyme; Ang I, angiotensin I; Ang II, angiotensin II; AT1R, angiotensin type 1 receptor; B2R, bradykinin type 2 receptor; ENaC, epithelial Na+ channel; MR, mineralocorticoid receptor. Dotted arrows represent inactive mechanisms of ENaC regulation under particular sodium intake.

References

    1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223. - PubMed
    1. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002;1:621–636. - PubMed
    1. Seva PB, van der LN, Verdonk K, et al. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol. 2013;9:26–36. - PubMed
    1. Crowley SD, Coffman TM. Recent advances involving the renin-angiotensin system. Exp Cell Res. 2012;318:1049–1056. - PMC - PubMed
    1. Bonde MM, Olsen KB, Erikstrup N, et al. The angiotensin II type 1 receptor antagonist losartan binds and activates bradykinin b2 receptor signaling. Regul Pept. 2011;167:21–25. - PubMed

Publication types

MeSH terms